Oncotelic Announces Peer-Reviewed Validation of Deciparticle(TM) Platform Supporting Clinical Development of Sapu003

Stock Information for NCS Multistage Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About NCS Multistage Holdings Inc.

Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle(TM) Technology Supporting the Ongoing Clinical Development of Sapu003 (IV everolimus)
Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway
Oncotelic Launches AI-Powered GMP Manufacturing Services Platform at BIO International Convention 2026
Oncotelic Advances AI-Powered GMP Manufacturing Services Platform for Revenue-Generating AI and Robotics Manufacturing Services
Oncotelic Showcases PDAOAI(TM) Capability in Advancing Drug Development. Featured in Qdrant Vector Space Day 2026 Keynote
NetworkNewsAudio Announces Audio Press Release (APR) Discussing the Exploration of Nanoparticle, Targeted Drug-Delivery Technologies
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Eyeing Nanotech-Driven Delivery Systems, Pharmacokinetic Optimization to Advance Existing Oncology Therapies
Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.